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Abstract
Background: Although infections caused by nontuberculous mycobacteria (NTM) are increasing in prevalence,
there are few data about hemoptysis in patients with NTM lung disease. This study investigated the characteristics
and prognosis of hemoptysis secondary to NTM infection.
Methods: Following a retrospective review of cases managed between 2006 and 2016, 183 patients with NTM lung
disease were enrolled and analyzed.
Results: Among 183 patients with NTM lung disease, Mycobacterium intracellulare (n= 64, 35%) was the major cause of
NTM infection, followed by M. avium (n = 59, 32.2%) and M. abscessus complex (n= 40, 21.9%). Hemoptysis developed in
78 patients (42.6%), among whom 33 (42.3%) required bronchial artery embolization (BAE). Between patients with and
without hemoptysis, there were no significant differences with respect to sex, radiographic manifestations, distribution
over 3 lobes on chest computed tomography, history of pulmonary tuberculosis, antiplatelet or anticoagulation therapy,
and species of NTM. However, mean age at diagnosis was significantly lower in the hemoptysis group in univariate and
multivariate analyses (65.7 ± 12.8 vs. 59.7 ± 11.8, P = 0.002, odds ratio: 0.969, 95% confidence interval: 0.944–0.996). Among
patients with hemoptysis, those requiring medical therapy and those requiring BAE were not significantly different in
terms of demographic characteristics, radiographic manifestations, and distribution over 3 lobes. All patients who received
BAE showed immediate clinical improvement, no procedure-related complications, and none of them died during the
period under review.
Conclusions: NTM lung disease patients commonly experienced hemoptysis without specific risk factors except for
relatively young age. Although some patients with hemoptysis needed BAE, the success rate of BAE was high, and there
were no serious complications associated with BAE.
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Background
The prevalence of human infection with nontuberculous
mycobacteria (NTM), an emerging cause of chronic pul-
monary disease, is gradually increasing worldwide [1, 2].
Most NTM have low pathogenicity, and they are widely
distributed in natural environments, such as soil and
water sources [3]. It is difficult to distinguish among
NTM colonization, contamination, and infection. The
American Thoracic Society (ATS) and the Infectious
Disease Society of America (IDSA) reported diagnosis
criteria for NTM infection with composite and complex
contents in 2007 [4].
There are more than 150 known NTM species, and new
species have recently been discovered [3]. Although there
are regional differences, Mycobacterium avium complex,
Mycobacterium kansasii, and Mycobacterium abscessus
complex (MABSC) are known major pathogens associated
with pulmonary diseases [5, 6]. The initiation of treatment
for NTM disease depends on various factors, such as
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individual clinical course, comorbidities, and adverse ef-
fects of antimycobacterial therapy. Furthermore, long-
term treatment is required after initiation [4]. Hemoptysis
is among the various potential clinical features of NTM
disease, regardless of treatment [3].
The severity of hemoptysis ranges from blood-tinged
sputum to massive hemoptysis, and it can be life-
threatening depending on the cause and severity [7]. In
Korea, pulmonary tuberculosis is known to be the lead-
ing cause of hemoptysis, and there are many studies on
pulmonary tuberculosis and hemoptysis [8, 9]. However,
there are few data about hemoptysis among patients
with NTM lung disease in Korea as well as in other
countries. This study investigated the characteristics and
prognosis of NTM lung disease with hemoptysis.
Methods
Study design and study subjects
This study was performed through a retrospective review
of medical records at Ewha Womans University Mokdong
Hospital, a tertiary referral hospital in Seoul, Korea. We
reviewed 272 patients who had at least one NTM isolation
in the sputum or bronchial lavage specimen culture be-
tween January 2006 and December 2016. Among them,
207 patients were diagnosed with NTM lung disease ac-
cording to the ATS/IDSA diagnostic criteria [4]; 183 pa-
tients with available medical records were included in the
final analysis. The enrolled patients were divided into two
groups according to the occurrence of hemoptysis. Pa-
tients with hemoptysis received medical management
when the amount of hemoptysis was low or vital signs
were stable, and further management—such as bronchial
artery embolization (BAE) and surgery—was considered if
the hemoptysis persisted or the vital signs were unstable.
We evaluated the development rate of hemoptysis, the
characteristics of hemoptysis patients, and the complica-
tions that occurred among patients who underwent BAE.
Data and definitions
Data for all enrolled patients were collected from the hos-
pital’s electronic medical records. We recorded various
demographic and comorbidity data, including sex, age,
and body mass index, as well as the presence of diabetes
mellitus (DM) and hypertension. We also noted the ad-
ministration of antiplatelet and anticoagulation medica-
tion, which may be associated with hemoptysis. All
enrolled patients underwent chest X-ray and chest com-
puted tomography (CT) scans, which were reviewed retro-
spectively by the same chest radiologist (SS Shim). For the
purposes of this study, we evaluated chest CT images
from when hemoptysis was present for patients with
hemoptysis; for patients without hemoptysis, we used the
most recent follow-up chest CT images. Radiologic find-
ings were classified as either nodular bronchiectatic type
or fibrocavitary type. The extent of lung involvement was
classified as either localized disease with involvement of 1
to 3 lobes or extensive disease with involvement of 4 to 5
lobes. Potential comorbidities were compared using the
Charlson Comorbidity Index [10].
Hemoptysis was defined as the patient who underwent
chest CT scan for hemoptysis evaluation. We excluded
patients who did not undergo CT scan when defining
hemoptysis. BAE was defined by actual embolizations;
this definition did not include simple angiographies. The
analysis included 33 consecutive patients who under-
went BAE performed by two interventional radiologists
(SY Choi, MW Kim). Medications, including antitus-
sives, antibiotics, and tranexamic acid, were used for pa-
tients who had hemoptysis but did not undergo BAE.
Statistical analysis
Results for all continuous variables are reported as mean ±
standard deviation, and all categorical variables are re-
ported as numbers and percentages. Between groups, con-
tinuous variables were analyzed using t-tests, and
categorical variables were analyzed using the χ2 test and
Fisher’s exact test. Multivariate analysis was performed
using the results of initial univariate analysis and logistic
regression. All statistical analyses were performed using
SPSS version 23.0 (IBM Corp., Armonk, NY, USA). In all
comparisons, a P-value of < 0.05 was considered statisti-
cally significant.
Results
Baseline characteristics
The baseline characteristics of enrolled patients from
January 2006 to December 2016 are summarized in
Table 1. Among 183 patients, there were 74 males
(40.4%), and the mean age at diagnosis was 62.9 ± 12.7
years. Mycobacterium intracellulare (n = 64, 35%) was
the most frequent cause of NTM infection, followed by
Mycobacterium avium (n = 59, 32.2%), MABSC (n = 40,
21.9%). Fiberoptic bronchoscopy was conducted on 53%
of patients for the diagnosis of NTM infection or evalu-
ation of hemoptysis. Patients with the nodular bronch-
iectatic type of NTM disease were more common than
those with the fibrocavitary type (n = 155, 84.7% vs. n =
28, 15.3%, respectively). Of the 155 patients with nodular
bronchiectatic NTM disease, 113 had localized disease,
and 42 had extensive disease. Of the 28 patients with
fibrocavitary NTM disease, 12 had localized disease, and
16 had extensive disease. During a mean follow-up
period of 48.7 ± 37.8 months, 78 patients (42.6%) devel-
oped hemoptysis, and 33 of 78 (42.3%) developed
hemoptysis requiring BAE. No patients underwent sur-
gery to treat hemoptysis.
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Comparison of groups
For comparison, enrolled patients were divided into two
groups according to the occurrence hemoptysis (Table 2).
There was no significant difference between the groups in
terms of follow-up duration, the proportion of male sex,
radiologic finding classification, extent of lung involve-
ment, presence of pulmonary tuberculosis history, anti-
platelet/anticoagulation therapy, and species of NTM.
However, patients in the hemoptysis group tended to be
younger than those without hemoptysis (mean age 65.7 ±
12.8 vs. 59.7 ± 11.8 years, P = 0.002). Additionally, patients
without hemoptysis had a significantly higher DM preva-
lence than those with hemoptysis (18.1% vs. 7.7%, P =
0.043). In the multivariate analysis including sex, the pres-
ence of a pulmonary tuberculosis history, and variables
with P-values < 0.1 from the univariate analysis, only age
at diagnosis showed a statistically significant between-
group difference (odds ratio: 0.969, 95% confidence inter-
val: 0.944–0.996, P = 0.023).
Analysis of group with hemoptysis
Of 78 patients with hemoptysis, 33 patients received BAE,
and 45 patients received medical treatment (Table 3). All
patients who received BAE showed immediate clinical im-
provement, and there were no patients who required sur-
gery for hemoptysis. Among patients with hemoptysis,
those requiring medical therapy and those requiring inter-
vention therapy with BAE were not significantly different
in terms of demographic characteristics, radiologic find-
ings, extent of lung involvement, and comorbidity index.
Additionally, there were no procedure-related complica-
tions or deaths, and there was no hemoptysis-related
mortality. Eight of the 33 patients who underwent BAE
subsequently underwent repeat BAE due to rebleeding,
and the median interval between first and second BAE was
10months (interquartile range 7.5–53.5month). Four pa-
tients experienced recurrent hemoptysis within 12months
after the first BAE, and three of them required more than
two more BAEs (total 8, 5, and 5 BAEs, respectively). On
the other hand, 12 out of the 45 patients who received
medical therapy experienced recurrence of their
hemoptysis. Recurrent hemoptysis in both groups was
mainly the nodular bronchiectatic type. However, patients
in the BAE group were mainly infected with MABSC, and
patients who received medical treatment were mainly in-
fected with Mycobacterium avium complex. Table 4 shows
the clinical characteristics among recurrent hemoptysis pa-
tients after BAE and medical therapy.
Discussion
This study investigated the clinical characteristics, the de-
velopment rate of hemoptysis requiring BAE, and the
treatment of hemoptysis among NTM lung disease pa-
tients. Many patients with NTM lung disease experienced
hemoptysis (42.6%) regardless of amount, and 18% of
NTM lung disease patients required BAE. No significant
risk factors for hemoptysis were determined other than
relatively young age. Many patients (33/78, 42.3%) re-
ceived nonmedical treatment for their hemoptysis, and
BAE was preferred to surgical treatment. Furthermore,
BAE was not associated with significant adverse events,
and patients who experienced recurrence within 12
months were more likely to require BAE treatment.
Table 1 Demographic and clinical characteristics
Characteristics N = 183
Male sex 74 (40.4)
Age at diagnosis, years 63.1 ± 12.7
BMI, kg/m2 20.0 ± 3
Diabetes mellitus 25 (13.7)
Hypertension 47 (25.7)
Antiplatelet or anti-coagulation 21 (11.5)
History of pulmonary tuberculosis 65 (35.5)
Hemoptysis 78 (42.6)
Occurrence of bronchial artery embolization 33 (18.0)
Surgical management of hemoptysis 0 (0)
Radiologic finding of NTM lung diseases
Nodular bronchiectatic 155 (84.7)
≤ 3 lobes 113 (61.7)
> 3 lobes 42 (23.0)
Fibrocavitary 28 (15.3)
≤ 3 lobes 12 (6.6)
> 3 lobes 16 (8.7)
Distribution of chest CT
≤ 3 lobes 125 (68.3)
> 3 lobes 58 (31.7)
Follow up duration, months 48.7 ± 37.8
NTM species identified from pulmonary specimens
M. avium 59 (32.2)
M. intracellulare 64 (35.0)
M. abscessus 40 (21.9)
M. kansasii 6 (3.3)
M. fortuitum 2 (1.1)
M. heckeshornense 1(0.5)
M. szulgai 1(0.5)
M. avium +M. intracellulare 2 (1.1)
M. avium +M abscessus 4 (2.2)
M. intracellulare + M. abscessus 3 (1.6)
M. abscessus + M. tuberculosis 1 (0.5)
Results are presented as n (%) or mean ± standard deviation, unless
otherwise indicated
BMI body mass index, NTM nontuberculous mycobacteria, CT computed
tomography, M. Mycobacterium
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Until now, NTM lung disease was known to cause
hemoptysis through pulmonary parenchymal infection
[11]; however, it is not considered a major cause of
hemoptysis. Although the causes of hemoptysis vary
from country to country—bronchitis, bronchogenic
carcinoma, bronchiectasis, Paragonimus westermani in-
fection, and pulmonary tuberculosis are known to be
common causes [8, 12–14]. However, our findings dem-
onstrated that many NTM lung disease patients experi-
ence hemoptysis requiring BAE.
Recently, the prevalence of NTM lung disease has
been gradually increasing worldwide, and its onset is
known to be associated with old age [1, 15, 16]. As the
global population continues to age, and many countries
already have aging or aged societies [17], the proportion
of NTM lung disease is expected to increase, and the
frequency of NTM lung disease-associated hemoptysis is
expected to increase.
In the multivariate analysis, relatively young age was
revealed as an independent risk factor. Unfortunately,
this observation is difficult to explain. However, regard-
ing pulmonary tuberculosis, some studies have reported
that hemoptysis was significantly more common among
younger people [18, 19]; the assumption is that the more
aggressive immune response among younger patients
may be more likely to induce hemoptysis [20]. Similarly,
Table 2 Comparison of groups with and without hemoptysis
Univariate Multivariate
Without hemoptysis
(n = 105)
With hemoptysis
(n = 78)
P-value OR (95% CI)
Male sex 47 (44.8) 27 (34.6) 0.167 1.211 (0.632–2.321)
Age, years, at diagnosis 65.7 ± 12.8 59.7 ± 11.8 0.002 0.969 (0.943–0.996)
BMI, kg/m2 20.0 ± 3.3 20.2 ± 2.7 0.758
Diabetes mellitus 19 (18.1) 6 (7.7) 0.043 0.508 (0.179–1.441)
Hypertension 32 (30.5) 15 (19.2) 0.085 0.870 (0.398–1.903)
Follow-up duration, months 48.3 ± 36.1 49.2 ± 37.9 0.864
Performed bronchoscopy 45 (42.9) 52 (66.7) 0.002
Type of chest CT
Nodular bronchiectatic 89 (84.8) 66 (84.6) 0.978
Fibrocavitary 16 (15.2) 12 (15.4)
Distribution of chest CT
≤ 3 lobes 67 (64.4) 58 (74.4) 0.129
> 3 lobes 38 (36.2) 20 (25.6)
Antiplatelet/anticoagulation therapy 11(10.5) 10 (12.8) 0.646
Liver disease 7 (6.7) 9 (11.5) 0.080 1.117 (0.668–1.869)
History of pulmonary tuberculosis 34 (32.4) 31 (39.7) 0.303 1.366 (0.726–2.572)
Charlson Comorbidity Index score 1.5 ± 1.8 1.3 ± 1.6 0.315
NTM species identified
M. avium 31 (29.5) 28 (35.9) 0.181
M. intracellulare 44 (41.9) 20 (25.6)
M. abscessus 20 (19.0) 20 (25.6)
M. kansasii 4 (3.8) 2 (2.6)
M. fortuitum 1 (1.0) 1(1.3)
M. heckeshornense 0 1(1.3)
M. szulgai 0 1(1.3)
M. avium +M. intracellulare 0 2(2.6)
M. avium +M. abscessus 3 (2.9) 1 (1.3)
M. intracellulare + M. abscessus 1 (1) 2 (2.6)
M. abscessus + M. tuberculosis 1(1) 0
Results are presented as n (%) or mean ± standard deviation, unless otherwise indicated
BMI body mass index, OR odds ratio, CI confidence interval, CT computed tomography, NTM nontuberculous mycobacteria, M. Mycobacterium
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in our study, NTM lung disease may have also caused
more hemoptysis among relatively young individuals via
a more aggressive immune response. Additionally, our
study showed that the occurrence and severity (requiring
BAE or not) of hemoptysis among NTM lung disease pa-
tients was not associated with chest CT patterns, severity
of involvement, or species of NTM pathogen. Although
patients with cavities on chest CT were expected to ex-
perience severe hemoptysis as well as recurrence, there
was no difference compared to those with bronchiectatic
CT features. This may be because the great majority of the
study sample did not have cavitary lung disease, or be-
cause bronchiectasis itself is a major risk factor for
hemoptysis [9]. Therefore, clinicians need to consider the
possibility of hemoptysis in young patients with NTM re-
gardless of severity and extent of lung involvement.
BAE has been used as the first-line therapy, or a bridge to
surgical treatment, for massive hemoptysis [14]. With im-
proved technology, the overall success and immediate clin-
ical success rates of BAE have been reported to be as high
as over 90 and 73% to 99% [14]. Although several guide-
lines and studies have reported that NTM lung disease can
cause hemoptysis, the treatment of hemoptysis has not
been extensively detailed, with some studies briefly men-
tioning surgical treatment [3, 4, 21–23]. However, this study
demonstrated that BAE is a good treatment option for
hemoptysis in NTM lung disease, like other diseases which
can cause hemoptysis [7]. There was immediate clinical
success and no serious complications for all patients who
underwent BAE during the period under review.
About one-quarter of BAE patients developed recurrent
hemoptysis in this study. Some studies have reported re-
currence in 10 to 20% patients over follow-up periods
between 6 and 12months [24–26]. Considering the dur-
ation (median 10months) between first BAE and rebleed-
ing in this study, BAE for hemoptysis in NTM lung
disease showed a similar recurrence rate to BAE for
hemoptysis in other diseases [24–26]. Causes of rebleed-
ing include incomplete embolization, revascularization, or
recanalization [24–26]. Some studies have found pulmon-
ary tuberculosis and aspergillus to be risk factors for the
recurrence of hemoptysis [27, 28]. However, although we
did not perform the relevant statistical analysis due to the
small sample size, the presence of lung damage from
Table 3 Comparison of BAE and non-BAE subjects with hemoptysis
Medical (n = 45) BAE (n = 33) P-value
Male sex 12 (26.7) 15 (45.5) 0.098
Age, years, at diagnosis 59.5 ± 11.7 60.0 ± 12.1 0.855
BMI, kg/m2 20.5 ± 2.6 19.8 ± 2.9 0.274
Diabetes mellitus 2 (4.4) 4 (12.1) 0.392
Hypertension 8 (17.8) 7 (21.2) 0.704
Performed bronchoscopy 28 (62.2) 24 (72.7) 0.466
Type of chest CT
Nodular bronchiectatic 38 (84.4) 28 (84.8) 0.961
Fibrocavitary 7 (15.6) 5 (15.2)
> 3 lobe distribution of chest CT 8 (17.8) 12 (36.4) 0.073
Antiplatelet/anticoagulation therapy 5 (11.1) 5 (15.2) 0.735
Liver disease 4 (8.9) 5 (15.2) 0.726
History of pulmonary tuberculosis 15 (33.3) 16 (48.5) 0.242
Charlson Comorbidity Index score 1.04 ± 1.1 1.6 ± 2.0 0.119
2 NTM pathogens identified 4 (8.9) 1 (3.0) 0.389
Complication after BAE 0
Repeat BAE due to rebleeding 8 (24.2)
Duration between first BAE and rebleedinga 10 (7.5–53.5)a
Number of BAE trials
1 25 (75.8)
2 5 (15.2)
5 2 (6.1)
8 1 (3.0)
Results are presented as n (%) or mean ± standard deviation, unless otherwise indicated
BAE bronchial artery embolization, BMI body mass index, CT computed tomography, NTM nontuberculous mycobacteria, M. Mycobacterium
athis value is presented as median (interquartile range) because of the small number of subjects
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previous pulmonary tuberculosis did not appear to affect
recurrence in this study. It was notable that most rebleed-
ing patients were infected with MABSC and had nodular
bronchiectatic radiologic findings on chest CT. Although
this finding is hard to generalize due to the small number
of patients with recurrent hemoptysis, considering that
MABSC is relatively difficult to treat and can also progress
with a fulminant course and that bronchiectasis features
on chest CT include hypertrophy and tortuosity of the
bronchial arteries [14, 29], these may be suggested as risk
factors for the recurrence of hemoptysis.
This study had some limitations, including its retrospect-
ive design and that it was performed at a single center.
Therefore, in our study, data regarding the rate of
hemoptysis, hemoptysis volume, indication for BAE, and the
techniques used for BAE—including late hemoptysis during
the follow-up period after diagnosis—were not always avail-
able and may not be accurately reported. Additionally, we
could not review the first presentations among the NTM
lung disease patients or the role of bronchoscopy among
these patients. This study did not reveal how NTM treat-
ment affected the occurrence or recurrence of hemoptysis
because we could not find consistent indications for NTM
treatment in this study. Finally, subjects in this study had a
higher prevalence of pulmonary tuberculosis history com-
pared with other studies because Korea has a high preva-
lence of tuberculosis [1, 8, 30]. It is, therefore, difficult to
generalize the results of this study to countries with low
rates of tuberculosis. However, this study is meaningful be-
cause, to our knowledge, it is the first study of hemoptysis
in NTM lung disease. As the prevalence of NTM disease in-
creases, prospective studies about hemoptysis in NTM lung
disease may be needed.
Conclusion
NTM lung disease patients commonly experienced
hemoptysis without specific risk factors except for relatively
young age. Some patients with hemoptysis required BAE,
the success rate of BAE was high, and there were no serious
complications associated with BAE. Therefore, BAE could
be considered a suitable treatment option for hemoptysis in
NTM lung disease.
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